Chronic myelogenous leukemia at blast crisis with a T-cell phenotype (T-ALL CML-BC) at diagnosis, without any prior history of CML is extremely rare. After the introduction of tyrosine kinase inhibitors (TKIs), CML patients have a median survival comparable to general population and accelerated/blast crisis are rarely encountered. Most CML patients (80%) transform into acute myeloid leukemia and the rest into B-ALL. Anecdotal cases of Ph+ T-ALL, either de novo or in the context of CML-BC have been reported. Left shift in the blood, the presence of splenomegaly/extramedullary infiltration and the occurrence of BCR::ABL1 rearrangement in both the blastic population, as well as in the myeloid cell compartment are key points in differentiating de novo Ph+ T-ALL from T-ALL CML-BC. The latter is a rare entity, characterized by extramedullary disease, p210 transcript and clonal evolution. Lack of preceding CML does not rule out the diagnosis of T-ALL CML-BC. Prompt TKI treatment with ALL-directed therapy followed by allogeneic stem cell transplantation may offer long-term survival in this otherwise poor prognosis entity. In this paper, we describe a patient with T-ALL CML-BC at presentation, still alive 51 months after diagnosis and we offer a review of the literature on this rare subject. All clinical and laboratory features are provided in order to distinguish de novo Ph+ T-ALL from T-ALL CML-BC, underscoring the prognostic and therapeutic significance of such a differentiation.

Journal Section:
Case Report
Keywords:
T-cell blast crisis, Chronic myeloid leukemia, Allogeneic bone marrow transplantation
1.
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European Leukemia Net 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–84.
https://doi.org/10.1038/s41375-020-0776-2
2.
Jain P, Kantarjian H, Jabbour E, Kanagal-Shamanna R, Patel K, Pierce S, et al. Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias-(De novo and blast phase CML). Am J Hematol. 2017;92(1):E3–4.
https://doi.org/10.1002/ajh.24579
3.
Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson T. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34(24):2851–7.
https://doi.org/10.1200/JCO.2015.66.2866
4.
Hochhaus A, Larson R, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917–27.
https://doi.org/10.1056/NEJMoa1609324
5.
Kantarjian H, Hughes T, Larson R, Kim DW, Issaragrisil S, le Coutre P, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35(2):440–53.
https://doi.org/10.1038/s41375-020-01111-2
6.
Raanani P, Trakhtenbrot L, Rechavi G, Rosenthal E, Avigdor A, Brok-Simoni F, et al. Philadelphia-chromosome-positive T-lymphoblastic leukemia: acute leukemia or chronic myelogenous leukemia blastic crisis. Acta Haematol. 2005;113(3):181–9.
https://doi.org/10.1159/000084448
7.
Dorfman DM, Longtine JA, Fox EA, Weinberg DS, Pinkus GS. T–cell blast crisis in chronic myelogenous leukemia. Immunophenotypic and molecular biologic findings. Am J Clin Pathol. 1997;107(2):168–76.
https://doi.org/10.1093/ajcp/107.2.168
8.
Lima M, Coutinho J, Bernardo L, dos Anjos Teixeira M, Casais C, Canelhas A, et al. Philadelphia-positive T-cell acute lymphoblastic leukemia with polymyositis, migratory polyarthritis and hypercalcemia following a chronic myeloid leukemia. Ann Hematol. 2002;81(3):174–7.
https://doi.org/10.1007/s00277-001-0422-7
9.
Kim A, Goldstein S, Luger S, Van Deerlin V, Bagg A. Sudden Extramedullary T-lymphoblastic blast crisis in chronic myelogenous leukemia: a nonrandom event associated with imatinib?Am J Clin Pathol. 2008;129(4):639–48.
https://doi.org/10.1309/GTGTEQAFMV30W753
10.
Wei J, Huang M, Wang Y, Zhou J. Sudden extramedullary blast crisis of chronic myeloid leukemia manifesting as T-cell lymphoblastic lymphoma. Onkologie. 2013;36(3):119–22.
https://doi.org/10.1159/000348681
11.
Xu J, Li S. Unusual T-lymphoblastic blast phase of chronic myelogenous leukemia. Case Rep Hematol. 2014;2014:304359–5.
https://doi.org/10.1155/2014/304359
12.
Padhi P, Topalovski M, El Behery R, Cantu E, Medavarapu R. A rare case of chronic myelogenous leukemia presenting as T-cell lymphoblastic crisis. Case Rep Oncol Med. 2018;2018:1–4.
https://doi.org/10.1155/2018/7276128
13.
Xia T, Yang Y, Li G, Chang J, Li J, Ren F, et al. T- cell blast crisis of chronic myelogenous leukemia presented with coexisting p210 and p190 BCR-ABL transcripts and t(10;11)(q11;p15). J Clin Lab Anal. 2020;34(6):e23241.
https://doi.org/10.1002/jcla.23241
14.
Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol. 2005;23(18):4100–9.
https://doi.org/10.1200/JCO.2005.05.531
15.
Grossmann V, Kohlmann A, Zenger M, Schindela S, Eder C, Weissmann S, et al. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia. 2011;25(3):557–60.
https://doi.org/10.1038/leu.2010.298
16.
Berger R. Differences between blastic chronic myeloid leukemia and Ph –positive acute leukemia. Leuk Lymphoma. 1993;11(Suppl 1):235–7.
https://doi.org/10.3109/10428199309047892
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.